ATE119396T1 - Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin. - Google Patents

Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin.

Info

Publication number: ATE119396T1
Authority: AT; Austria
Prior art keywords: inhibin; activin; treatment; beta; globin
Prior art date: 1988-11-01

Application number

AT89311297T

Other languages

English (en)

Inventor

Susan P Perrine

Norbert Albers

Original Assignee

Susan P Perrine

Norbert Albers

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-01

Filing date

1989-11-01

Publication date

1995-03-15

1989-11-01 Application filed by Susan P Perrine, Norbert Albers filed Critical Susan P Perrine

1995-03-15 Application granted granted Critical

1995-03-15 Publication of ATE119396T1 publication Critical patent/ATE119396T1/de

Links

ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 title abstract 3
102000005606 Activins Human genes 0.000 title abstract 2
108010059616 Activins Proteins 0.000 title abstract 2
239000000488 activin Substances 0.000 title abstract 2
239000000893 inhibin Substances 0.000 title abstract 2
108010044495 Fetal Hemoglobin Proteins 0.000 title 1
102100021519 Hemoglobin subunit beta Human genes 0.000 abstract 2
108091005904 Hemoglobin subunit beta Proteins 0.000 abstract 2
108091005886 Hemoglobin subunit gamma Proteins 0.000 abstract 1
102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 abstract 1
208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
206010043391 Thalassaemia beta Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000007056 sickle cell anemia Diseases 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Food Science & Technology (AREA)
Biochemistry (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT89311297T 1988-11-01 1989-11-01 Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin. ATE119396T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/266,421 US4997815A (en)	1988-11-01	1988-11-01	Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin

Publications (1)

Publication Number	Publication Date
ATE119396T1 true ATE119396T1 (de)	1995-03-15

Family

ID=23014518

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT89311297T ATE119396T1 (de)	1988-11-01	1989-11-01	Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin.

Country Status (9)

Country	Link
US (1)	US4997815A (de)
EP (2)	EP0617966A1 (de)
JP (1)	JPH02256622A (de)
AT (1)	ATE119396T1 (de)
CA (1)	CA2001897A1 (de)
DE (1)	DE68921546T2 (de)
IL (1)	IL92167A (de)
MA (1)	MA21667A1 (de)
PT (1)	PT92174B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03173805A (ja) *	1989-09-11	1991-07-29	Ajinomoto Co Inc	卵分割促進剤
US5166190A (en) *	1990-01-08	1992-11-24	Genentech, Inc.	Method for increasing fertility in males
US5102868A (en) *	1990-01-08	1992-04-07	Genentech, Inc.	Method for inhibiting follicular maturation
US5942220A (en) *	1990-03-16	1999-08-24	Chiron Corporation	Inhibitor of cytokine activity and applications thereof
WO1991012334A1 (en) *	1990-02-15	1991-08-22	Cetus Corporation	Inhibitor of cytokine activity and applications thereof
EP0548276A4 (en) *	1990-09-13	1993-12-29	Children's Hospital Medical Center Of Northern California	Method for increasing red blood cell production by treatment with activin or activin-related peptides
US7910624B1 (en)	1995-03-03	2011-03-22	The Trustees Of Boston University	Compositions for the treatment of blood disorders
USD354971S (en)	1993-07-26	1995-01-31	Mugnier Design	Eyeglasses
US5487895A (en) *	1993-08-13	1996-01-30	Vitaphore Corporation	Method for forming controlled release polymeric substrate
AU7668894A (en) *	1993-08-13	1995-03-14	Vitaphore Corporation	Hydrogel-based microsphere drug delivery systems
WO1995011699A1 (en) *	1993-10-29	1995-05-04	The Trustees Of Boston University	Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
US5700640A (en) *	1994-09-16	1997-12-23	Basf Aktiengesellschaft	Inducers of gamma globin gene expression and screening assays therefor
US5545616A (en) *	1994-09-22	1996-08-13	Genentech, Inc.	Method for predicting and/or preventing preterm labor
US6011000A (en) *	1995-03-03	2000-01-04	Perrine; Susan P.	Compositions for the treatment of blood disorders
GB2306481A (en)	1995-10-21	1997-05-07	Univ Manchester	Pharmaceutical comprising a stimulator of activin and/or inhibin
AU3889197A (en)	1996-07-26	1998-02-20	Douglas V Faller	Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
AUPO638897A0 (en) *	1997-04-23	1997-05-22	Monash University	Modulation of cell growth and methods relating thereto
US6822267B1 (en) *	1997-08-20	2004-11-23	Advantest Corporation	Signal transmission circuit, CMOS semiconductor device, and circuit board
WO1999040883A2 (en) *	1998-02-11	1999-08-19	Faller Douglas V	Compositions and methods for the treatment of cystic fibrosis
EP1543110A4 (de)	2002-05-17	2006-09-06	Sinai School Medicine	Mesoderm- und definitive endoderm-zellpopulationen
US20060003446A1 (en)	2002-05-17	2006-01-05	Gordon Keller	Mesoderm and definitive endoderm cell populations
AU2012203441B2 (en) *	2002-05-17	2015-01-29	Mount Sinai School Of Medicine Of New York University	Mesoderm and definitive endoderm cell populations
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7381825B2 (en) *	2003-03-17	2008-06-03	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US20050159470A1 (en) *	2003-12-19	2005-07-21	Syrrx, Inc.	Histone deacetylase inhibitors
US20050137234A1 (en) *	2003-12-19	2005-06-23	Syrrx, Inc.	Histone deacetylase inhibitors
WO2006020683A1 (en) *	2004-08-10	2006-02-23	Voyager Pharmaceutical Corporation	Methods for treating premature infants
EP1824831A2 (de) *	2004-12-16	2007-08-29	Takeda San Diego, Inc.	Histondeacetylase-inhibitoren
EP1896436A2 (de) *	2005-05-11	2008-03-12	Takeda San Diego, Inc.	Inhibitoren der histondeacetylase
EA200800321A1 (ru) *	2005-07-14	2008-06-30	Такеда Сан Диего, Инк.	Ингибиторы гистондеацетилазы
JP2009525955A (ja) *	2006-01-13	2009-07-16	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
US8874380B2 (en)	2010-12-09	2014-10-28	Rutgers, The State University Of New Jersey	Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2010105112A1 (en) *	2009-03-11	2010-09-16	Hemaquest Pharmaceuticals, Inc.	Detection of short-chain fatty acids in biological samples
US20110086869A1 (en)	2009-09-24	2011-04-14	The Trustees Of Boston University	Methods for treating viral disorders
WO2011072086A1 (en)	2009-12-08	2011-06-16	Hemaquest Pharmaceuticals, Inc.	Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en)	2010-03-11	2011-09-15	Hemaquest Pharmaceuticals, Inc.	Methods and compositions for treating viral or virally-induced conditions
WO2013119800A1 (en)	2012-02-07	2013-08-15	Massachusetts Institute Of Technology	Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en)	2013-03-15	2017-08-08	Massachusetts Institute Of Technology	Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US20160106821A1 (en) *	2014-10-20	2016-04-21	Massachusetts Institute Of Technology	Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
US10317418B2 (en)	2015-02-24	2019-06-11	Massachusetts Institute Of Technology	Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
JP7158104B2 (ja)	2016-07-15	2022-10-21	ビラクタセラピューティクス，インク．	Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤
AU2020283590A1 (en)	2019-05-31	2022-01-20	Viracta Subsidiary, Inc.	Methods of treating virally associated cancers with histone deacetylase inhibitors
US11938143B2 (en)	2021-10-19	2024-03-26	Akirabio, Inc.	Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0730114B2 (ja) *	1985-04-03	1995-04-05	正雄五十嵐	インヒビン
JPH0637520B2 (ja) *	1985-07-03	1994-05-18	味の素株式会社	ポリペプチド
US4740587A (en) *	1985-07-18	1988-04-26	The Salk Institute For Biological Studies	Inhibin and method of purifying same
NZ217727A (en) *	1985-10-03	1990-05-28	Genentech Inc	Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
NZ217821A (en) *	1985-10-10	1989-07-27	Biotech Australia Pty Ltd	Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4822821A (en) *	1986-10-10	1989-04-18	Children's Hospital Medical Center Of Northern California	Method for augmenting fetal hemoglobin
DE3853383T2 (de) *	1987-01-29	1995-07-27	Biotech Australia Pty Ltd	Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
US5032507A (en) *	1987-11-13	1991-07-16	The Salk Institute For Biological Studies	Potentiation of erythropoiesis

1988
- 1988-11-01 US US07/266,421 patent/US4997815A/en not_active Expired - Fee Related
1989
- 1989-10-31 MA MA21919A patent/MA21667A1/fr unknown
- 1989-10-31 IL IL9216789A patent/IL92167A/en not_active IP Right Cessation
- 1989-10-31 CA CA002001897A patent/CA2001897A1/en not_active Abandoned
- 1989-11-01 AT AT89311297T patent/ATE119396T1/de active
- 1989-11-01 JP JP1286002A patent/JPH02256622A/ja active Pending
- 1989-11-01 DE DE68921546T patent/DE68921546T2/de not_active Expired - Fee Related
- 1989-11-01 EP EP94200748A patent/EP0617966A1/de not_active Withdrawn
- 1989-11-01 EP EP89311297A patent/EP0367590B1/de not_active Expired - Lifetime
- 1989-11-02 PT PT92174A patent/PT92174B/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT92174B (pt)	1995-09-12
DE68921546T2 (de)	1995-07-06
IL92167A (en)	1994-07-31
DE68921546D1 (de)	1995-04-13
EP0367590A2 (de)	1990-05-09
MA21667A1 (fr)	1990-07-01
PT92174A (pt)	1990-05-31
EP0367590B1 (de)	1995-03-08
EP0367590A3 (de)	1992-01-02
IL92167A0 (en)	1990-07-12
CA2001897A1 (en)	1990-05-01
JPH02256622A (ja)	1990-10-17
EP0617966A1 (de)	1994-10-05
US4997815A (en)	1991-03-05

Publication	Publication Date	Title
ATE119396T1 (de)	1995-03-15	Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin.
ATE130762T1 (de)	1995-12-15	Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
DK0396184T3 (da)	1996-12-30	Anvendelse af ketoconazol og et retinoid til behandling af acne vulgaris
FR2721516B1 (fr)	1996-09-13	Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation.
DE3062981D1 (en)	1983-06-09	Alkyl-urea derivatives for the treatment of lipometabolic diseases; process for their preparation, their use in medicaments for the treatment of lipometabolic disorders, medicaments containing them, process for the preparation of the medicaments, and some alkyl-urea derivatives
EP0371789A3 (de)	1991-10-02	Arzneimittel zur Erhöhung des Gehaltes an fötalem Hämoglobin
ATE69550T1 (de)	1991-12-15	Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen.
Antoniadis et al.	1989	Clinical study of sialolithiasis. Findings from 100 cases
Schor et al.	1983	Rotating grating treatment of amblyopia with and without eccentric fixation
Neubauer	1979	Carbon monoxide and hyperbaric oxygen
Chandra	1976	Some aspects of tuberculous meningitis in Surabaya
SU588982A1 (ru)	1978-01-25	Способ лечени сахарного диабета
SU1169655A1 (ru)	1985-07-30	Способ лечени тромбооблитерирующих заболеваний артерий конечностей
SU940377A1 (ru)	1983-08-15	Способ комплексного лечени звенной болезни желудка и двенадцатиперстной кишки
Mitchell	1932	Lead poisoning in children
Moon et al.	1989	Clinical Study of Kienbock's Disease
Bash	1979	Pernicious anemia in young black women
Lee et al.	1989	A Clinical Study of Transient Synovitis of the Hip Joint
TNSN90103A1 (fr)	1991-03-05	Procede pour augmenter l'hemoglobine foetale par traitement avec de l'activine et/ou de l'inhibine
Behrman et al.	1956	Alopecia Areata Due to Syphilis
DS	1983	Sexual dysfunctions in the male
RU93014662A (ru)	1995-07-27	Способ лечения плевритов
Gugler	1992	Mercury and the'Pains of Love'in Jonathan Swift's' A Beautiful Young Nymph Going to Bed'
宋宝珠 et al.	1985	SHORT-TERM EFFECT IN 135 CASES OF ENURESIS TREATED BY WRIST-ANKLE NEEDLING
Madden et al.	1980	Outpatient behavior therapy and biofeedback treatment of pain and related problems.